利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.04 秒)

    T cell receptor-deficient T cell compositions
    2.
    发明授权
    T cell receptor-deficient T cell compositions 有权

    公开(公告)号：US09028812B2

    公开(公告)日：2015-05-12

    申请号：US13502978

    申请日：2010-10-29

    申请人： Charles L. Sentman

    发明人： Charles L. Sentman

    IPC分类号： C12N5/10 ,  C12N5/0783 ,  A61K39/00

    摘要： The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

    Regulatory T cell mediator proteins and uses thereof
    4.
    发明授权
    Regulatory T cell mediator proteins and uses thereof 有权
    调节性T细胞介质蛋白及其用途

    公开(公告)号：US09217035B2

    公开(公告)日：2015-12-22

    申请号：US13901704

    申请日：2013-05-24

    申请人： Randolph J. Noelle ,  Li Wang

    发明人： Randolph J. Noelle ,  Li Wang

    IPC分类号： A61K38/00 ,  C07K14/705 ,  C07K16/28 ,  G01N33/50 ,  A61K39/00

    CPC分类号： C07K16/2827 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70596 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/505 ,  Y02A50/412 ,  Y02A50/423

    摘要： The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated Treg-sTNF. Proteins, antibodies, activated T cells and methods for using the same are disclosed.In particular methods of using these proteins and compounds, preferably antibodies, which bind or modulate (agonize or antagonize) the activity of these proteins, as immune modulators and for the treatment of cancer, autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis is disclosed.

    摘要翻译： 本发明涉及新型调节性T细胞蛋白。 称为PD-L3的一种蛋白质类似于PD-L1家族的成员，并且在体外共同刺激T细胞的αCD3增殖。 第二种TNF样蛋白也被鉴定为在αCD3/αGITR刺激下上调。 该蛋白质已被命名为Treg-sTNF。 公开了蛋白质，抗体，活化的T细胞及其使用方法。 特别是使用这些蛋白质和化合物（优选抗体）的方法，其结合或调节（激动或拮抗）这些蛋白质的活性，作为免疫调节剂和用于治疗癌症，自身免疫疾病，变态反应，感染和炎性病症，例如， 公开了多发性硬化。

    Method and system for port performance ranking in multi-protocol switch
    6.
    发明授权
    Method and system for port performance ranking in multi-protocol switch 有权

    公开(公告)号：US09654423B2

    公开(公告)日：2017-05-16

    申请号：US14197599

    申请日：2014-03-05

    申请人： Wipro Limited

    发明人： Madhukar Gunjan Chakhaiyar

    IPC分类号： H04L12/931

    CPC分类号： H04L49/602 ,  H04L49/356 ,  H04L49/50

    摘要： A system and method for port performance ranking in a multi-protocol switch includes monitoring one or more first parameters, the one or more first parameters associated with operating condition of one or more ports of the multi-protocol switch. Each of the one or more first parameters is compared with an associated predefined criterion to determine deviation from the associated predefined criterion. One or more eligible ports is determined from the one or more ports based on non-deviation of each of the one or more first parameters from the associated predefined criterion. For each of the one or more eligible ports, each of one or more second parameters is compared with an associated predefined threshold, the one or more second parameters associated with port traffic statistics. The one or more eligible ports are ranked based on the comparison between each of the second parameters and the associated predefined threshold.

    Antagonists of IL-6 to prevent or treat thrombosis
    9.
    发明授权
    Antagonists of IL-6 to prevent or treat thrombosis 有权
    IL-6拮抗剂可预防或治疗血栓形成

    公开(公告)号：US09212223B2

    公开(公告)日：2015-12-15

    申请号：US13600978

    申请日：2012-08-31

    申请人： Jeffrey T. L. Smith

    发明人： Jeffrey T. L. Smith

    IPC分类号： A61K39/395 ,  C07K16/24 ,  A61K45/06 ,  C12P21/08 ,  A61K39/00

    CPC分类号： C07K16/248 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

    摘要： The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.

    摘要翻译： 本发明涉及使用具有IL-6结合特异性的抗体及其片段的IL-6拮抗剂以预防或治疗与异常血液凝固或纤维蛋白溶解有关的疾病中的血栓形成的治疗方法。 在优选实施方案中，这些患者将包括那些表现出升高的D-二聚体或其他凝血级联相关蛋白的那些，并且任选地将在治疗之前进一步显示升高的C反应蛋白。 主题疗法还可以包括施用其它活性物质，例如化学治疗剂，抗凝血剂，他汀类药物等。